Sumitomo Mitsui DS Asset Management Company Ltd Increases Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,679 shares of the medical equipment provider’s stock after purchasing an additional 449 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Zimmer Biomet were worth $2,396,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. BLB&B Advisors LLC increased its position in Zimmer Biomet by 2.1% during the third quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock worth $529,000 after buying an additional 100 shares in the last quarter. CKW Financial Group increased its position in Zimmer Biomet by 11.7% during the 4th quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock worth $101,000 after purchasing an additional 100 shares in the last quarter. FWG Holdings LLC raised its stake in Zimmer Biomet by 2.9% in the 3rd quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider’s stock valued at $372,000 after purchasing an additional 101 shares during the last quarter. Romano Brothers AND Company lifted its holdings in Zimmer Biomet by 1.1% in the 4th quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock valued at $1,000,000 after purchasing an additional 102 shares in the last quarter. Finally, Financial Advocates Investment Management boosted its stake in shares of Zimmer Biomet by 3.5% during the 3rd quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock worth $330,000 after purchasing an additional 103 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on ZBH. Wells Fargo & Company upped their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. JMP Securities reissued a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research note on Friday. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research report on Friday. Stifel Nicolaus increased their target price on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Finally, JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Stock Down 0.5 %

Shares of NYSE ZBH opened at $100.40 on Tuesday. The stock has a fifty day moving average price of $107.34 and a 200 day moving average price of $108.07. The company has a market cap of $19.99 billion, a P/E ratio of 22.56, a P/E/G ratio of 1.83 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12-month low of $99.67 and a 12-month high of $133.90. The company has a current ratio of 1.91, a quick ratio of 0.70 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the company posted $2.20 EPS. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.25 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.96%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.